Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Lenalidomide in conjunction with proteasome inhibitors post-stem cell transplant

Thomas Martin • 14 Sep 2019
IMW 2019
Multiple Myeloma Bortezomib Lenalidomide

Thomas Martin, MD, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA discusses the use of lenalidomide as a maintenance-based therapy, and the possibility to use it in conjunction with a proteasome inhibitor such as bortezomib in myeloma patients. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Thomas Martin

4:03
IKEMA long-term sub-group analysis: Isa-Kd for 1q21+ multiple myeloma
Thomas Martin • 11 Sep 2023
2:57
Considerations for mitigating CAR-T resistance in multiple myeloma
Thomas Martin • 11 Sep 2023
4:14
Challenges with the real-world use of CAR-T therapy in multiple myeloma
Thomas Martin • 11 Sep 2023
9:52
Myeloma highlights from SOHO 2023: updates with the use of novel targeted immunotherapies
Thomas Martin • 11 Sep 2023

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals